[go: up one dir, main page]

WO2013166264A3 - Methods for altering virus replication - Google Patents

Methods for altering virus replication Download PDF

Info

Publication number
WO2013166264A3
WO2013166264A3 PCT/US2013/039234 US2013039234W WO2013166264A3 WO 2013166264 A3 WO2013166264 A3 WO 2013166264A3 US 2013039234 W US2013039234 W US 2013039234W WO 2013166264 A3 WO2013166264 A3 WO 2013166264A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
viral replication
virus
altering
virus replication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/039234
Other languages
French (fr)
Other versions
WO2013166264A2 (en
Inventor
Ralph A. Tripp
Stephen M. Tompkins
Abhijeet BAKRE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Georgia
University of Georgia Research Foundation Inc UGARF
Original Assignee
University of Georgia
University of Georgia Research Foundation Inc UGARF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Georgia, University of Georgia Research Foundation Inc UGARF filed Critical University of Georgia
Publication of WO2013166264A2 publication Critical patent/WO2013166264A2/en
Publication of WO2013166264A3 publication Critical patent/WO2013166264A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided herein are methods for altering viral replication in a cell. The virus may be a member of the family Orthomyxoviridae, such as an influenza virus, or a member of the family Paramyxoviridae, such as human respiratory syncytial virus. Altering viral replication is accomplished through the use of polynucleotides. In one embodiment, a polynucleotide decreases expression of a polypeptide, such as a protease or a kinase. In one embodiment, a polynucleotide is an miRNA or an miRNA inhibitor. In some embodiments viral replication is decreased, and in other embodiments viral replication is increased. Also included are methods for treating a subject, and genetically modified cells having the characteristic of altered virus replication compared to a control cell.
PCT/US2013/039234 2012-05-02 2013-05-02 Methods for altering virus replication Ceased WO2013166264A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261641664P 2012-05-02 2012-05-02
US61/641,664 2012-05-02

Publications (2)

Publication Number Publication Date
WO2013166264A2 WO2013166264A2 (en) 2013-11-07
WO2013166264A3 true WO2013166264A3 (en) 2014-01-16

Family

ID=49515035

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/039234 Ceased WO2013166264A2 (en) 2012-05-02 2013-05-02 Methods for altering virus replication

Country Status (1)

Country Link
WO (1) WO2013166264A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11279929B2 (en) 2018-07-03 2022-03-22 Hoffmann-La Roche, Inc. Oligonucleotides for modulating Tau expression

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017007784A1 (en) * 2015-07-06 2017-01-12 University Of Georgia Research Foundation Methods and compositions related to increased influenza virus production
CN108603188A (en) * 2015-11-24 2018-09-28 联邦科学技术研究组织 Virus is generated in cell culture
KR20180079448A (en) 2015-11-24 2018-07-10 커먼웰쓰 사이언티픽 앤드 인더스트리얼 리서치 오가니제이션 Virus production in avian eggs
MA45496A (en) 2016-06-17 2019-04-24 Hoffmann La Roche NUCLEIC ACID MOLECULES FOR PADD5 OR PAD7 MRNA REDUCTION FOR TREATMENT OF HEPATITIS B INFECTION
WO2018136758A1 (en) 2017-01-23 2018-07-26 Regeneron Pharmaceuticals, Inc. Hsd17b13 variants and uses thereof
RU2019135845A (en) 2017-04-11 2021-05-11 Ридженерон Фармасьютикалз, Инк. TESTS FOR SCREENING THE ACTIVITY OF MODULATORS OF FAMILY MEMBERS (17-BETA) HYDROXYSTEROID DEHYDROGENASE (HSD17B)
CA3078883A1 (en) 2017-10-11 2019-04-18 Regeneron Pharmaceuticals, Inc. Inhibition of hsd17b13 in the treatment of liver disease in patients expressing the pnpla3 i148m variation
RU2766360C2 (en) 2017-10-16 2022-03-15 Ф. Хоффманн-Ля Рош Аг Nucleic acid molecules for reducing papd5 or papd7 mrna levels for treating infectious hepatitis b
MX2020009812A (en) 2018-03-21 2021-01-08 Regeneron Pharma ARNI COMPOSITIONS OF 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) AND METHODS OF USE THEREOF.
CA3123890A1 (en) * 2019-01-04 2020-07-09 Cargill Incorporated Engineered nucleases to generate mutations in plants
CN110261611B (en) * 2019-06-14 2021-06-22 上海四核生物科技有限公司 Application of ZNF709 protein as gastric cancer serum biomarker and kit thereof
EP4464779A3 (en) * 2020-02-14 2025-06-25 The Board of Trustees of the Leland Stanford Junior University Pan-genotypic agents against respiratory viruses and methods of using the same
WO2022119560A1 (en) * 2020-12-01 2022-06-09 National Health Research Institutes Cell strain having increased virus production ability and production method thereof
KR20240033228A (en) * 2021-06-16 2024-03-12 엠피리코 인크. Treatment of MST1-related diseases and disorders
EP4603586A1 (en) * 2024-02-16 2025-08-20 Universität zu Lübeck Inhibitory oligonucleotides against adamts7
CN118236389B (en) * 2024-05-28 2024-09-24 南京晖丽生物科技有限公司 Application of miR-3120 in preparation of pharmaceutical composition for preventing and treating tumor and tumor cachexia
CN120789265A (en) * 2025-09-05 2025-10-17 中国人民解放军军事科学院军事医学研究院 Application of miRNA in preventing or treating postoperative atrial fibrillation diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057461A2 (en) * 2001-01-18 2002-07-25 Bayer Aktiengesellschaft Regulation of human adam-ts-like zinc metalloprotease
US20090170720A1 (en) * 2004-10-15 2009-07-02 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
WO2011017535A2 (en) * 2009-08-05 2011-02-10 University Of South Florida Method of rapidly visualizing essential neural pathways
WO2012045067A2 (en) * 2010-10-01 2012-04-05 Zirus, Inc. Mammalian genes involved in infection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057461A2 (en) * 2001-01-18 2002-07-25 Bayer Aktiengesellschaft Regulation of human adam-ts-like zinc metalloprotease
US20090170720A1 (en) * 2004-10-15 2009-07-02 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
WO2011017535A2 (en) * 2009-08-05 2011-02-10 University Of South Florida Method of rapidly visualizing essential neural pathways
WO2012045067A2 (en) * 2010-10-01 2012-04-05 Zirus, Inc. Mammalian genes involved in infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MELIOPOULOS.: "UNDERSTANDING HOST PROTEASE GENE INVOLVEMENT DURING INFLUENZA VIRUS REPLICATION AS A POTENTIAL DISEASE INTERVENTION STRATEGY", DOCTORAL DISSERTATION, December 2011 (2011-12-01), pages 1 - 222 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11279929B2 (en) 2018-07-03 2022-03-22 Hoffmann-La Roche, Inc. Oligonucleotides for modulating Tau expression
US11753640B2 (en) 2018-07-03 2023-09-12 Hoffmann-La Roche Inc. Oligonucleotides for modulating Tau expression

Also Published As

Publication number Publication date
WO2013166264A2 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
WO2013166264A3 (en) Methods for altering virus replication
WO2014123967A3 (en) Cell lines for virus production and methods of use
Li et al. LSQR iterative method for generalized coupled Sylvester matrix equations
IL261372A (en) Preparation, uses and solid forms of obeticholic acid
CN104812762A8 (en) Substituted annulated pyrimidines and triazines, and use thereof
WO2014159822A3 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
WO2016037154A8 (en) Recombinant hiv-1 envelope proteins and their use
WO2014197568A3 (en) Rna-guideded transcriptional regulation
WO2013151666A3 (en) Modified polynucleotides for the production of biologics and proteins associated with human disease
HK1206601A1 (en) Modified polynucleotides for the production of biologics and proteins associated with human disease
BR112015002516A2 (en) dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of viral disease.
CO6811861A2 (en) Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
EP3070163A4 (en) Method for preparing induced pluripotent stem cell, composition used in method, and uses thereof
EP3561054C0 (en) FEEDER-FREE DERIVATION OF HUMAN-MADE PLURIPOTENTS STEM CELLS WITH SYNTHETIC MESSAGER RNA
WO2012103496A3 (en) Expression of soluble viral fusion glycoproteins in mammalian cells
HK1221405A1 (en) Matrix metalloproteinases and uses thereof
EP2811023A4 (en) VECTOR FOR THE SIMULTANEOUS EXPRESSION OF DODECAMERIC PATH AND HSV-TK SELF-MOMENTS, AND STEM CELL TREATMENT THEREWITH
WO2015017316A3 (en) Methods and compositions for modifying mucous membranes
EP2964754A4 (en) HEPATOCELLULAR HEPATOCELLULAR CARCINOMA STEM CELLS WITH HIGH PURITY, METHODS AND USE THEREOF
EP3007710A4 (en) Cell populations, methods of transdifferention and methods of use thereof
WO2013124807A3 (en) Oligonucleotides for modulating gene expression and uses thereof
WO2014177541A3 (en) Glucoamylase variants and polynucleotides encoding same
HK1256159A1 (en) Immuno-oncology mesodermal progenitor (iomp) cell
PL3022297T3 (en) Genetically stable oncolytic rna virus, method of manufacturing and use thereof
HK1206984A1 (en) Combination therapy of anti-mif antibodies and glucocorticoids

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13785192

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13785192

Country of ref document: EP

Kind code of ref document: A2